Blog

Mar 21, 2021

HDL Update: Age-Related Changes, All-Cause Mortality Risk, And Progress Towards The Optimal Range

Posted by in categories: biotech/medical, life extension, sex

Here’s my latest video!


In November 2020, I made a HDL video based on a meta-analysis in ~3.4 million subjects that was published in July 2020. In Dec 2020, a larger study (n=15.8 million subjects) was published-those data are presented in the video, and compared against the meta-analysis.

In addition, I’ve tested my HDL 2 more times since November 2020, so how’s my progress for getting it into the optimal range? Also, I attempt to derive clinical significance by identifying correlations for higher HDL with lower Lp(a) and hs-CRP.

Studies referenced in the video:
High-density lipoprotein cholesterol and all-cause mortality by sex and age: a prospective cohort study among 15.8 million adults:
https://pubmed.ncbi.nlm.nih.gov/33313654/

HDL-C is associated with mortality from all causes, cardiovascular disease and cancer in a J-shaped dose-response fashion: a pooled analysis of 37 prospective cohort studies:
https://pubmed.ncbi.nlm.nih.gov/32283957/

Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association:
https://pubmed.ncbi.nlm.nih.gov/31147269/

CRP studies:
Beta2-microglobulin for risk stratification of total mortality in the elderly population: comparison with cystatin C and C-reactive protein:
https://pubmed.ncbi.nlm.nih.gov/31147269/

High-Sensitivity C-Reactive Protein and Risks of All-Cause and Cause-Specific Mortality in a Japanese Population:
https://pubmed.ncbi.nlm.nih.gov/27268644/

Comments are closed.